New drug could protect children with cancer from chemo side effects

NCT ID NCT04570423

Recruiting now Disease control Sponsor: Spectrum Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: eflapegrastim (a drug to boost white blood cells)
What this could lead to: If it works, this could offer a safer way to prevent severe infections in children undergoing chemotherapy for cancer.
What could go wrong: This is a small, early-phase study focused on safety, not yet proven to work. Side effects or lack of benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA SOLID TUMORS

Contacts and locations

Locations

Carolinas Medical Center/ Levine Children's Hospital
TERMINATED

Charlotte, North Carolina, 28203, United States
Levine Children's Health
TERMINATED

Charlotte, North Carolina, 28203, United States
New York Medical College
TERMINATED

Valhalla, New York, 10595, United States
UT MD Anderson Cancer Center
TERMINATED

Houston, Texas, 77030, United States
University Hospitals Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.